Key Market Indicator:
In this news category you will find information from and about companies, organizations, institutions, products of all kinds and in a broad spectrum. To get a quick overview of current trends and developments, it's worth visiting daily.
DE000A11QVV0
Thu, 25.09.2025
Heidelberg Pharma AG
PRESS RELEASE
Heidelberg Pharma Advances to Cohort 9 in Phase I/IIa Trial of Lead ATAC Candidate HDP-101 in Multiple Myeloma
HDP-101 continues to demonstrate a favorable safety profile with no dose-limiting toxicities observed
Early evidence of clinical activity observed in Cohort 8, highlighted by a very good partial response observed in one pa [ … ]
Thu, 25.09.2025
Heidelberg Pharma AG
PRESS RELEASE
Heidelberg Pharma Significantly Reduces Operating Costs and Focuses on Lead ADC Candidate HDP-101 Due to Delayed Milestone Payment
Milestone payment of USD 70 million from royalty financing agreement with HealthCare Royalty delayed as payment condition has not yet been met
Clinical Phase I/IIa trial with HDP-101 in Multiple Myelom [ … ]
Thu, 04.09.2025
Heidelberg Pharma AG
PRESS RELEASE
Heidelberg Pharma Announces New Clinical Data on Lead ATAC Candidate HDP-101 to be Presented at International Myeloma Society Annual Meeting 2025
Ladenburg, Germany, 4 September 2025 – Heidelberg Pharma AG (FSE: HPHA), a clinical stage company developing innovative Antibody Drug Conjugates (ADCs), today announces that new data from [ … ]
Thu, 10.07.2025
Heidelberg Pharma AG
PRESS RELEASE
Heidelberg Pharma Reports on First Half-Year 2025 and the Positive Course of Business
Clinical trial with ATAC candidate HDP-101 in multiple myeloma shows promising data
Cohort 7 of the Phase I dose escalation study with HDP-101 safe and well tolerated; Cohort 8 started
First patient in clinical study dosed with the second ATAC c [ … ]
Tue, 27.05.2025
Heidelberg Pharma AG
PRESS RELEASE
Heidelberg Pharma Announces First Patient Dosed in Phase I Study of Amanitin-based ADC Candidate HDP-102 for Non-Hodgkin Lymphoma
Ladenburg, Germany, 27 May 2025 – Heidelberg Pharma AG (FSE: HPHA), a clinical-stage biotech company developing innovative Antibody Drug Conjugates (ADCs), today announced that the first patient has been [ … ]
Thu, 15.05.2025
Heidelberg Pharma AG
PRESS RELEASE
Heidelberg Pharma Reports on the Results of the Ordinary Annual General Meeting 2025 and New Supervisory Board
All agenda items approved by a large majority
2025 Annual General Meeting elects Dr Karl Benedikt Biesinger and Dr Klaus Schollmeier as new members of the Supervisory Board
Supervisory Board elects Dr Karl Benedikt Biesin [ … ]
Wed, 14.05.2025
Heidelberg Pharma AG
PRESS RELEASE
Heidelberg Pharma to Present Promising New Clinical Data on its Lead ATAC Candidate HDP-101 at EHA 2025
HDP-101 demonstrated complete response in one female patient from cohort 5
R&D Webinar to be hosted on 17 June 2025
Ladenburg, Germany, 14 May 2025 – Heidelberg Pharma AG (FSE: HPHA), a clinical-stage biotech company developi [ … ]
Thu, 24.04.2025
Heidelberg Pharma AG
Heidelberg Pharma AG: Interim Statement on the First Three Months of Financial Year 2025
Cohort 7 of the clinical trial of HDP-101 in multiple myeloma safe and well tolerated
Cohort 8 expected to start soon
Clinical development of the second ADC program HDP-102 in patients with non-Hodgkin lymphoma (NHL) has started
Amendment of contract with [ … ]
Wed, 26.03.2025
Heidelberg Pharma AG
PRESS RELEASE
Heidelberg Pharma to Present Data from its ADC Technology Platforms at AACR Annual Meeting 2025
Ladenburg, Germany, 26 March 2025 – Heidelberg Pharma AG (FSE: HPHA), a clinical-stage biotech company developing innovative Antibody Drug Conjugates (ADCs), today announced that it will be presenting its latest ADC research results and [ … ]
Fri, 21.03.2025
Heidelberg Pharma AG
PRESS RELEASE
Heidelberg Pharma announces financial figures and reports on successful business performance in 2024
Promising data from clinical trial with HDP-101 in multiple myeloma, including a complete remission in one female patient; study is making good progress
Received first approvals for the clinical study with ATAC candidate HDP-102; st [ … ]
